Core Insights - Kyverna has made significant progress in 2025, reporting positive top-line results from its pivotal study for the autologous CD19 CAR-T therapy, miv-cel, in Stiff-Person syndrome [1] - The company anticipates a transformative period in 2026, with expectations for a Biologics License Application (BLA) submission to address a significant unmet need in a rare disease [1] Company Highlights - The leadership team has undertaken transformative work over the past 18 months to position the company as a leader and differentiate it from competitors in the CAR-T therapy space [2] - The miv-cel construct is unique and specifically designed to enhance therapeutic outcomes [2]

Kyverna Therapeutics Conference Call Summary Company Overview - **Company**: Kyverna Therapeutics (NasdaqGS:KYTX) - **Focus**: Development of autologous CAR T therapies, specifically targeting rare autoimmune diseases Key Highlights from 2025 and Early 2026 - **Positive Results**: Kyverna reported positive top-line results from pivotal studies for miv-cel, an autologous CD19 CAR T therapy for stiff person syndrome, indicating a transformative period ahead in 2026 with a BLA submission expected in the first half of the year [3][5] - **Unique Construct**: Miv-cel is a second-generation CAR T therapy designed for improved potency, efficacy, and safety, with a tenfold reduction in high-grade CRS and ICANS compared to traditional CAR Ts [4][10] Stiff Person Syndrome (SPS) - **Unmet Need**: SPS has no FDA-approved therapies, with 80% of patients progressing to severe disability, highlighting a significant unmet medical need [12] - **Clinical Impact**: Miv-cel demonstrated a 46% reduction in the timed 25-foot walk test by the 16-week primary endpoint, significantly exceeding the clinically meaningful response threshold of 20% [14][15] - **BLA Filing**: Kyverna is on track to file for BLA approval by the end of 2026, potentially becoming the first autologous CAR T therapy approved for autoimmune diseases [13][21] Regulatory and Manufacturing Insights - **FDA Engagement**: Continuous positive interactions with the FDA, including RMAT and orphan drug designations, provide confidence in the approval pathway [21] - **Manufacturing Success**: A 95% manufacturing success rate has been achieved in clinical trials, with plans to scale up for launch [22][55] Commercial Strategy - **Target Patient Population**: Approximately 6,000 patients in the U.S. with SPS, with 2,000-2,500 being refractory to existing treatments, representing the initial target market [27] - **Pricing Strategy**: Kyverna plans to justify a premium pricing model based on the health economic burden of SPS and the potential to eliminate chronic therapies [25][26] Myasthenia Gravis (MG) Development - **Next Indication**: Myasthenia gravis is viewed as a valuable market opportunity, with a significant patient population of 80,000, of which 12,000-13,000 are refractory to existing therapies [48] - **Pivotal Phase 3 Study**: Actively enrolling patients with a unique randomized design to compare miv-cel against standard care, aiming for superiority in clinical outcomes [45][46] Pipeline and Future Opportunities - **Neuroimmunology Franchise**: Kyverna is building a portfolio beyond SPS and MG, with promising early data in progressive MS showing significant improvements in patient outcomes [57][58] - **KYV-102 Development**: A next-generation manufacturing process that utilizes whole blood, improving patient access and reducing costs, is in the IND submission stage [59][61] Conclusion - Kyverna Therapeutics is positioned for a transformative year in 2026 with significant advancements in its CAR T therapies for rare autoimmune diseases, a strong regulatory pathway, and a focused commercial strategy targeting high unmet needs in SPS and MG [3][5][21]

Core Insights - Kyverna Therapeutics is set to present key findings from its KYSA-8 trial for Stiff Person Syndrome (SPS) and updated data from the KYSA-6 trial for generalized myasthenia gravis (gMG) at the American Academy of Neurology Annual Meeting in April 2026 [1][2] Company Overview - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead product being miv-cel (KYV-101), a CD19-targeting CAR T-cell therapy [9] - The company aims to redefine treatment paradigms for SPS and myasthenia gravis through innovative therapies [2][9] Clinical Trials and Presentations - The oral presentation for the KYSA-8 trial will showcase the efficacy and safety of miv-cel in treating SPS, with a focus on reversing progressive disability [3][4] - Updated Phase 2 results for the KYSA-6 trial will be presented, which investigates miv-cel's potential to achieve durable, drug-free, disease-free remission with a single dose in gMG patients [2][3] Disease Context - Stiff Person Syndrome (SPS) is a rare autoimmune disease characterized by muscle stiffness and spasms, leading to significant mobility issues, with no FDA-approved treatments currently available [5] - Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular disease that causes muscle weakness and fatigue, affecting approximately 80,000 patients in the U.S. [6][7] Product Information - Miv-cel is designed for potency and tolerability, aiming for deep B-cell depletion and immune system reset, which could lead to long-lasting remission in autoimmune diseases [8]

Core Insights - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [2] Group 1: Upcoming Conferences - Company management will participate in the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 11:20 a.m. ET [1] - The company will also attend the 2026 Jefferies Biotech on the Beach Summit on March 10, 2026, for investor meetings [1] - A live webcast of the Leerink fireside chat will be available on the company's website, with a replay accessible for 90 days post-conference [1] Group 2: Company Overview - Kyverna's lead therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), targets CD19 and aims to change treatment paradigms for B-cell-driven autoimmune diseases [2] - The company is advancing a neuroimmunology franchise with initial indications in stiff person syndrome and myasthenia gravis [2] - Additional studies are being conducted in multiple sclerosis and rheumatoid arthritis to inform future indications and develop next-generation CAR T platforms [2]

Core Insights - The biotech sector is anticipated to enter a transformative phase with significant advancements in treatments for diseases such as cancer, Alzheimer's, and autoimmune disorders [2] - Technological innovations are expected to accelerate, with developments in fusion energy, solid-state batteries, and nanomaterials becoming more prevalent [2] Company and Industry Analysis - The analyst has a long position in KYTX, indicating a belief in the company's potential for growth [3] - The analyst's background in engineering physics and applied mathematics informs a quantitative approach to stock research, integrating complex mathematical models with macroeconomic factors [2]

Core Viewpoint - Kyverna Therapeutics has appointed Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors, enhancing its leadership team as the company advances towards commercialization of its cell therapies for autoimmune diseases [1][3]. Group 1: Board Appointments - Sravan K. Emany will serve as the Audit Committee Chair, succeeding Dan Spiegelman, who has stepped down from the Board [2]. - Andrew Miller, Ph.D. is recognized for his extensive experience in clinical development and product approval, which will support Kyverna's growth [1][3]. Group 2: Leadership Experience - Sravan Emany has a strong background in financial leadership, currently serving as CFO of Beam Therapeutics, and has held significant roles in investment banking, including at Bank of America and Goldman Sachs [3][4]. - Dr. Andrew Miller was the Founder and President of R&D at Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion in 2024, and has been recognized as one of Time Magazine's 100 Next Generation Leaders [4]. Group 3: Company Overview - Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, with its lead candidate, miv-cel, showing potential to change treatment paradigms for B-cell-driven autoimmune diseases [5]. - The company is advancing its neuroimmunology franchise with completed and ongoing registrational trials for conditions such as stiff person syndrome and generalized myasthenia gravis [5].

Core Insights - Wall Street analysts are showing strong confidence in four clinical-stage biotech companies, with potential price targets indicating gains of up to 384% [1] - These companies are characterized by significant risks but have compelling late-stage pipelines and upcoming catalysts that attract institutional investors [1] Company Summaries EyePoint Pharmaceuticals - Current trading price is $12.94 with a consensus target of $36.08, suggesting a 179% upside [2] - The lead candidate, Duravyu, targets diabetic macular edema and wet age-related macular degeneration, with pivotal Phase 3 trials starting in Q1 2026 [2] - Q3 2025 revenue was $5.33 million, down from $10.52 million a year prior, with a net loss of $59.4 million and cash reserves of $71.1 million [3] - All 13 analysts rate it Buy or Strong Buy, with the stock having doubled over the past year but down 29% year-to-date [3] Janux Therapeutics - Trading at $13.14 with a consensus target of $63.59, indicating a 384% potential upside [4] - The company’s TRACTr and TRACIr platforms are designed for tumor-activated T-cell engagement, with two candidates in clinical trials [4] - Q3 2025 revenue surged to $10.0 million from $439,000 a year earlier, with a net loss of $24.31 million and R&D expenses nearly doubling to $34.63 million [5] - Cash position stands at $989 million, with all 19 analysts rating it Buy or Strong Buy [5] Kyverna Therapeutics - Currently trading at $7.26, with analysts targeting $29.60, implying a 308% upside [6] - The lead candidate, KYV-101, is in late-stage trials for stiff person syndrome and myasthenia gravis, with positive interim data supporting its clinical thesis [6][7] - Q3 2025 net loss was $36.8 million, better than estimates, and the company has secured a $150 million loan facility alongside $171.1 million in cash [7] - All six analysts rate it Buy or Strong Buy, with the stock having surged 139% over the past year [7] Viking Therapeutics - Trading at $29 with a consensus target of $92.72, representing a 220% upside [8] - The lead drug, VK2735, is a dual GLP-1/GIP agonist in Phase 3 trials, with significant patient enrollment [8] - Q4 2025 net loss was $157.7 million, missing estimates, while R&D expenses increased significantly [9] - Cash reserves are at $706 million, with 17 out of 18 analysts rating it Buy or Strong Buy [9] Industry Overview - The four companies represent high-conviction investments in clinical-stage biotech, with Viking's obesity market positioning offering the largest potential opportunity [10] - Kyverna's CAR T approach addresses unmet needs in autoimmune diseases, while Janux's platform technology provides multiple avenues for success [10] - EyePoint's more mature pipeline includes near-term catalysts, and all four companies carry inherent clinical-stage risks but have strong analyst support indicating favorable risk-reward profiles for patient investors [10]

Core Insights - Kyverna Therapeutics has appointed Mayo Pujols as Chief Technology Officer, effective February 9, 2026, to support the launch of its CAR T-cell therapy, miv-cel [1][2][3] Company Overview - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead candidate being miv-cel (mivocabtagene autoleucel, KYV-101) [7] - The company aims to revolutionize treatment for B-cell-driven autoimmune diseases and is advancing its neuroimmunology franchise with ongoing registrational trials [7] Leadership Transition - Mayo Pujols brings over 30 years of experience in technical operations, particularly in cell and gene therapies, succeeding Karen Walker, who is retiring but will assist in the transition [2][3] - Pujols has held significant roles in various biopharmaceutical companies, including COO at Castle Creek Biosciences and CTO at Rocket Pharmaceuticals, where he guided gene therapy programs through regulatory milestones [3][4] Miv-cel Therapy - Miv-cel is a fully human, autologous CAR T-cell therapy targeting CD19, designed for potency and tolerability, and is under investigation for B-cell-driven autoimmune diseases [6] - The therapy has the potential to achieve deep B-cell depletion and reset the immune system, aiming for durable, drug-free remission in autoimmune conditions [6] Inducement Grant - In connection with Pujols' appointment, Kyverna will grant him an option to purchase 300,000 shares of common stock, which will vest over four years [5]

Summary of Kyverna Therapeutics FY Conference Call Company Overview - **Company**: Kyverna Therapeutics (NasdaqGS:KYTX) - **Focus**: Development of CAR T therapies for autoimmune diseases, specifically targeting Stiff Person Syndrome (SPS) and Myasthenia Gravis (MG) [2][3] Key Points and Arguments Clinical Progress - **Transformative Year**: 2025 was described as a transformative year for Kyverna, with significant advancements in clinical data for SPS and MG [2][3] - **Patient Outcomes**: - In SPS trials, patients showed dramatic improvements in mobility, with one patient reducing their 25-foot walk test time from 17.3 seconds to 4.5 seconds (74% reduction) [4][5] - Over 80% of patients experienced clinically meaningful responses to therapy [12] - Patients previously reliant on walking aids were able to walk normally post-treatment [12] - **Regulatory Pathway**: A clear regulatory pathway has been established with the FDA for both SPS and MG, with plans to file a Biologics License Application (BLA) for SPS in the first half of 2026 [20][21] Market Opportunity - **SPS Market Size**: Approximately 6,000 diagnosed patients in the U.S., with 2,000 to 2,500 being particularly in need of new therapies [25][26] - **Economic Burden**: Current off-label treatments like IVIG cost hundreds of thousands of dollars annually without effective results, highlighting the economic value of Kyverna's therapy [26][40] - **Patient Demographics**: The majority of SPS patients are of working age, emphasizing the urgency for effective treatment to improve their quality of life [26] Commercialization Strategy - **First Mover Advantage**: Kyverna aims to leverage its first mover advantage in the CAR T space for autoimmune diseases, with plans to activate new treatment centers and engage with patient advocacy groups [22][23][27] - **Manufacturing Preparedness**: The company has validated manufacturing processes with a 95% success rate, ensuring readiness for commercial demand [50] Future Developments - **Pipeline Expansion**: Kyverna is exploring additional indications such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), and Lupus Nephritis, with promising early data [28][29] - **Next-Generation Therapy**: KYV-102, a second-generation CAR T therapy, has been filed for IND, aiming to simplify patient access and reduce costs [51][52] Competitive Landscape - **Differentiation**: Kyverna's approach focuses on deep B-cell depletion and resetting the immune system, which distinguishes it from other therapies, including T-cell engagers [45][46] - **Long-Term Vision**: The company is positioned to address high unmet needs in autoimmune diseases, with a focus on executing its strategy effectively [48][49] Additional Important Insights - **Physician Feedback**: Physicians treating SPS patients expressed surprise and excitement over the significant improvements seen in clinical trials, indicating a strong unmet need in the market [34][35] - **Pricing Strategy**: The company anticipates a premium pricing model for its CAR T therapy, justified by the substantial cost savings and benefits it offers compared to existing treatments [40][41] This summary encapsulates the key points discussed during the conference call, highlighting Kyverna Therapeutics' advancements, market opportunities, and strategic plans for the future.

Pioneering CAR T in Autoimmune Diseases JP Morgan Healthcare Conference January 2026 Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. ("Kyverna", "we", "our," or the "Company"). All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward looking statements inclu ...